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ABSTRACT
Background Exposure to parental smoking is associated
with wheeze in early childhood, but in 2006 the US
Surgeon General stated that the evidence is insufficient
to infer a causal relationship between exposure and
asthma in childhood and adolescents.
Aims To examine the association between maternal and
paternal smoking and symptoms of asthma, eczema and
rhinoconjunctivitis.
Methods Parents or guardians of children aged
6e7 years completed written questionnaires about
symptoms of asthma, rhinoconjunctivitis and eczema,
and several risk factors, including maternal smoking in
the child’s first year of life, current maternal smoking
(and amount) and paternal smoking. Adolescents aged
13e14 years self completed the questionnaires on these
symptoms and whether their parents currently smoked.
Results In the 6e7-year age group there were 220 407
children from 75 centres in 32 countries. In the 13e14-
year age group there were 350 654 adolescents from
118 centres in 53 countries. Maternal and paternal
smoking was associated with an increased risk of
symptoms of asthma, eczema and rhinoconjunctivitis in
both age groups, although the magnitude of the OR is
higher for symptoms of asthma than the other outcomes.
Maternal smoking is associated with higher ORs than
paternal smoking. For asthma symptoms there is a clear
dose relationship (1e9 cigarettes/day, OR 1.27; 10e19
cigarettes/day, OR 1.35; and 20+ cigarettes/day, OR
1.56). When maternal smoking in the child’s first year of
life and current maternal smoking are considered, the
main effect is due to maternal smoking in the child’s first
year of life. There was no interaction between maternal
and paternal smoking.
Conclusions This study has confirmed the importance
of maternal smoking, and the separate and additional
effect of paternal smoking. The presence of
a doseeresponse effect relationship with asthma
symptoms suggests that the relationship is causal,
however for eczema and rhinoconjunctivitis causality is
less certain.
The effect of environmental tobacco smoke expo-
sure (ETS) on respiratory health has been of
interest for many years. In 2006 the US Surgeon
General concluded that ‘the evidence is sufﬁcient to
infer a causal relationship between secondhand
smoke exposure from parental smoking and the
onset of wheeze illnesses in early childhood’ and
‘that the evidence is suggestive but not sufﬁcient to
infer a causal relationship between secondhand
smoke exposure from parental smoking and the
onset of childhood asthma’.1 While a recent
systematic review and meta-analysis has quantiﬁed
the strength of the associations,2 the data come
predominantly from developed countries. The
importance of the age of exposure to ETS is not
well established, nor is the relative importance of
maternal and paternal smoking.
In contrast with the number of studies exam-
ining the association of ETS with asthma, there are
fewer studies examining the association between
ETS and either eczema or rhinoconjunctivitis, and
these have provided conﬂicting results.
The aims of this study were to examine the
association between maternal and paternal
smoking and symptoms of asthma, rhino-
conjunctivitis and eczema, to assess the relative
importance of maternal and paternal smoking, to
look for consistency in these ﬁndings from many
different countries, including developing countries,
and to determine if there is a doseeresponse
effect, which if present would support a causal
relationship.
Key messages
What is the key question?
< What is the association between maternal and
paternal smoking and symptoms of asthma,
eczema and rhinoconjunctivitis?
What is the bottom line?
< This study has confirmed the association of
maternal smoking, and identified a separate and
additive association between paternal smoking
and the risk of symptoms of asthma, eczema
and rhinoconjunctivitis.
Why read on?
< The results of this large study (over 570 000
children and adolescents in 53 countries) were
consistent throughout the world and were
independent of the income of the country.
< Additional tables are
published online only. To view
these files please visit the
journal online (http://dx.doi.org/
10.1136/thoraxjnl-2011-
200901).
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METHODS
International Study of Asthma and Allergies in Childhood
(ISAAC) Phase Three is a multicentre, multicountry, cross-
sectional study of children (aged 6e7 years) and adolescents
(aged 13e14 years) chosen from a random sample of schools in
a deﬁned geographical area. The parent or guardian completed
the questionnaire for the children and for the adolescents the
questionnaire was self-completed. The methods have been
described in detail previously.3
Outcomes
Current wheeze was identiﬁed by a positive response to the
question: ‘Has your child/have you had wheezing or whistling
in the chest in the past 12 months?’
Severe asthma symptoms were identiﬁed by fulﬁlling one or
more of the following criteria:
1. Four or more attacks of wheezing in the past 12 months.
2. Sleep disturbance due to wheezing occurring one or more
nights per week in the past 12 months.
3. Wheezing limiting speech to one or two words at a time
between breaths in the past 12 months.
Asthma (the diagnosis) was deﬁned as a positive response to
the question: ‘Has your child/have you ever had asthma?’
Current rhinoconjunctivitis was identiﬁed by a positive
response to each of the following questions:
1. In the past 12 months has your child/have you had a problem
with sneezing, or a runny or blocked nose when he/she did
not have a cold or the ﬂu?
2. If yes, has this nose problem been accompanied by itchy
watery eyes?
Current eczema was identiﬁed by a positive answer to each of
the following questions:
1. Has your child/have you ever had an itchy skin rash, which
was coming and going for at least 6 months?
2. If yes, has your child/have you had this itchy rash at any time
in the past 12 months?
3. If yes, has this itchy rash at any time affected any of the
following placesdthe folds of the elbows, behind the knees,
in front of the ankles, under the buttocks, or around the neck,
ears, or eyes?
The prevalence of wheeze and asthma is higher in children
with rhinoconjuctivitis and eczema,4 and this might account for
the association between parental smoking and eczema and
rhinoconjunctivitis; therefore, the risk of symptoms of eczema
and rhinoconjunctivitis in the absence of current asthma
symptoms was also examined.
In addition, a video questionnaire of asthma symptoms was
administered to the adolescents. The video question used was
the sequence on current wheeze at rest deﬁned as a positive
response to the question: ‘Has your breathing been like this in
the past year?’ The video asthma questionnaire was validated
against the written questionnaire.5
Explanatory variables
The following questions were used to assess smoking by the
parents of the subjects. For children aged 6e7 years:
1. Does your child’s mother (or female guardian) smoke
cigarettes?
If yes, about how many cigarettes does the child’s mother
(or female guardian) smoke each day?
2. Does your child’s father (or male guardian) smoke cigarettes?
If yes, about how many cigarettes does the child’s father
(or male guardian) smoke each day?
3. Did your child’s mother (or female guardian) smoke cigarettes
during your child’s ﬁrst year of life?
For adolescents aged 13e14 years:
1. Does your mother (or female guardian) smoke cigarettes?
2. Does your father (or male guardian) smoke cigarettes?
Table 1 Association between tobacco smoking by the parents and symptoms of asthma, eczema and
rhinoconjunctivitis at 6e7 and 13e14 years of age
Symptom Tobacco question
Age group
6e7 years 13e14 years
Current wheeze Current paternal smoking 1.17 (1.12 to 1.21) 1.20 (1.15 to 1.24)
Current maternal smoking 1.28 (1.22 to 1.34) 1.32 (1.26 to 1.37)
Mother smoked first year of life 1.36 (1.29 to 1.43) *
Current wheeze (video) Current paternal smoking * 1.22 (1.15 to 1.29)
Current maternal smoking * 1.41 (1.32 to 1.49)
Severe asthma symptoms Current paternal smoking 1.23 (1.16 to 1.30) 1.26 (1.20 to 1.32)
Current maternal smoking 1.32 (1.24 to 1.41) 1.38 (1.31 to 1.45)
Mother smoked first year of life 1.44 (1.33 to 1.55) *
Asthma ever Current paternal smoking 1.11 (1.06 to 1.15) 1.08 (1.04 to 1.12)
Current maternal smoking 1.26 (1.20 to 1.32) 1.20 (1.16 to 1.25)
Mother smoked first year of life 1.34 (1.27 to 1.42) *
Current eczema symptoms Current paternal smoking 1.09 (1.04 to 1.13) 1.19 (1.14 to 1.25)
Current maternal smoking 1.15 (1.09 to 1.21) 1.22 (1.16 to 1.28)
Mother smoked first year of life 1.20 (1.13 to 1.27) *
Current rhinoconjunctivitis Current paternal smoking 1.08 (1.04 to 1.13) 1.15 (1.11 to 1.19)
Current maternal smoking 1.12 (1.06 to 1.18) 1.20 (1.15 to 1.25)
Mother smoked first year of life 1.17 (1.10 to 1.24) *
Eczema without wheeze Current paternal smoking 1.06 (1.01 to 1.11) 1.15 (1.09 to 1.20)
Current maternal smoking 1.10 (1.03 to 1.17) 1.12 (1.05 to 1.18)
Mother smoked first year of life 1.11 (1.04 to 1.19) *
Rhinoconjunctivitis without wheeze Current paternal smoking 1.04 (0.99 to 1.09) 1.11 (1.07 to 1.16)
Current maternal smoking 1.05 (0.98 to 1.12) 1.11 (1.06 to 1.16)
Mother smoked first year of life 1.05 (0.98 to 1.13) *
Data are OR (95% CI) and are adjusted for gender, language, region and Gross National Income (GNI) category.
*Data not collected.
Asthma
Thorax 2012;67:941–949. doi:10.1136/thoraxjnl-2011-200901942
group.bmj.com on November 4, 2015 - Published by http://thorax.bmj.com/Downloaded from 
To assess the presence of a doseeresponse relationship, the
number of cigarettes smoked were categorised as 0, 1e9, 10e19
and 20+ per day. In addition, combinations of maternal and
paternal smoking were examined for both age groups, and
combinations of maternal smoking in the child’s ﬁrst year of life
and current maternal smoking were examined in the 6e7-year
age group.
Study sample
For the 6e7-year age group, data were submitted to the ISAAC
International Data Centre (IIDC) from 165 centres in 65 coun-
tries with 421 543 participants. There were 21 centres in 16
countries (32 732 children) excluded as the response rate was
<60% or there were <1000 participants. There were a further 69
centres in 38 countries (168 404 children) that did not include
the risk factor questionnaire. The ﬁnal risk factor dataset for the
younger age group comprised 75 centres from 32 countries with
220 407 children.
For the adolescent group, data from 242 centres in 98 countries
with 814 837 participants were submitted to the IIDC. There
were nine centres from six countries (16 152 adolescents) excluded
as the response rate was <70% or there were <1000 participants.
Figure 1 ORs for the association between current maternal smoking and current wheeze by country in children aged 6e7 years. For every country,
the percentage of children exposed to maternal smoking is stated in brackets.
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There were a further 111 centres from 59 countries (437086
adolescents) that did not include the risk factor questionnaire.
Four centres did not collect data on current maternal and paternal
smoking. The ﬁnal risk factor dataset for the older age
group comprised 118 centres from 53 countries with 350 654
adolescents.
In addition, some centres did not collect data on speciﬁc risk
factor questions or the response rate to the speciﬁc question was
Figure 2 ORs for the association between current maternal smoking and current wheeze by country in adolescents aged 13e14 years (Tokelau
excluded). For every country, the percentage of children exposed to maternal smoking is stated in brackets.
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<70%. For the 6e7-year age group the following number of
centres were excluded: current maternal smoking¼1, current
paternal smoking¼2, mother smoked in child’s ﬁrst year of
life¼3, amount smoked by mother¼5, and amount smoked by
father¼6; and for the 13e14-year age group: current maternal
smoking¼1 and current paternal smoking¼10.
Statistical analysis
To be included in the analysis, centres had to assess at least 1000
subjects (except Tokelau which was a complete country study)
and to have a response rate of >60% for the children and >70%
for the adolescents. Centres with minor deviations from
protocol were included in the analyses and identiﬁed by the use
of a footnote in the ISAAC publications.6e8 Odds ratios (ORs)
were calculated with generalised linear mixed models, with
a binomial distribution and logit link, and with centres being
modelled as a random effect. Analyses were adjusted for gender,
region of the world, language and gross national income. The
regression models allowed for the sampling by schools by scaling
the size of the sample by the design effect.
No imputation was done for missing data, as previous anal-
yses had shown that little or no bias was introduced by limiting
the multivariate analyses to children with complete data.9
To assess whether being in two smoke exposure groups,
relative to being in one or the other, resulted in disproportion-
ately high risk, the relative excess risk due to interaction and its
95% CIs were calculated.10
The population-attributable risk of current asthma symptoms
for maternal smoking was calculated with the Mantel-Haenszel
approach, with the adjusted relative risk (RR) and the
proportion of subjects who were exposed.11
RESULTS
Exposure values (6e7-year age group: current maternal smoking,
current paternal smoking and mother smoking in ﬁrst year of
the child’s life; 13e14-year age group: current maternal smoking
and current paternal smoking) and prevalence values (current
symptoms of asthma, rhinoconjunctivitis and eczema) by centre
are shown in online tables 1 (6e7 years old) and 2 (13e14 years
old).
Table 1 shows the association between smoking by the
parents and symptoms of asthma, rhinoconjunctivitis and
eczema at 6e7 and 13e14 years of age. Smoking is associated
with an increased risk of symptoms of asthma, eczema and
rhinoconjunctivitis. Figures 1 and 2 show the adjusted ORs for
the association between current maternal smoking and asthma
symptoms for each age group by country and table 2 shows
these associations by region. The ORs are higher for asthma
outcomes than for symptoms of rhinoconjunctivitis and
eczema. The magnitude of the ORs associated with symptoms
of eczema and rhinoconjunctivitis are similar, but weaker than
that seen with asthma outcomes. The ORs for the 6e7-year age
group are very similar to those for the 13e14-year age group. In
all analyses but one current maternal smoking is associated with
higher ORs than current paternal smoking; the exception is
symptoms of eczema without wheeze in the 13e14-year age
group. In all the 6e7-year age group analyses maternal smoking
in the child’s ﬁrst year of life is associated with higher ORs than
current maternal smoking. Furthermore, in both age groups
severe symptoms of asthma are associated with higher ORs than
current wheeze or asthma.
The association between all the smoking variables and
symptoms of eczema without current asthma symptoms in
both age groups are signiﬁcant. The association between the
smoking variables and symptoms of rhinoconjunctivitis without
current asthma symptoms is signiﬁcant for the 13e14-year age
group, but not for the younger age group, although the point
estimates are elevated.
For asthma in the 6e7-year age group (current wheeze, severe
symptoms and asthma) there is clear evidence of
a doseeresponse effect for current smoking by the mother and
father (table 3). For example, the more cigarettes the mother
currently smokes, the higher the risk of severe asthma symp-
toms (1e9 cigarettes/day, OR 1.27; 10e19 cigarettes/day, OR
1.35; 20+ cigarettes/day, OR 1.56). A doseeresponse effect is
not seen with symptoms of eczema and rhinoconjunctivitis.
The risk of all outcome variables is greater when the mother
only smokes than when the father only smokes (except for
symptoms of rhinoconjunctivitis without wheeze in the 13e14-
year age group) (table 4). When both the mother and father
smoke the risk is increased by the expected amount; that is, the
increased risk is almost exactly the same as that obtained by
multiplying the OR when the mother only smokes with that
when the father only smokes. There is no evidence of an inter-
action between these variables.
Table 5 examines the association between the combinations of
smoking in the child’s ﬁrst year of life and current maternal
smoking and symptoms of asthma, rhinoconjunctivitis and
eczema. Maternal smoking in the ﬁrst year of the child’s life
only is associated with greater risk of all symptoms than current
maternal smoking only, although there is also an effect of only
maternal smoking currently. Unexpectedly maternal smoking in
the ﬁrst year of life and currently is not associated with a further
increase in risk compared with that seen with smoking in the
ﬁrst year of the child’s life. There is a signiﬁcant negative relative
Table 2 The association between current maternal smoking and current asthma symptoms by region in
children aged 6e7 and 13e14 years
Region
Age group 6e7 years Age group 13e14 years
Centres (n) OR (95% CI) Centres (n) OR (95% CI)
Africa 1 5.31 (0.79 to 35.79) 10 1.37 (1.01 to 1.86)
Asia-Pacific 11 1.18 (1.00 to 1.40) 18 1.39 (1.19 to 1.63)
Eastern Mediterranean 6 1.48 (1.20 to 1.83) 8 1.28 (1.05 to 1.55)
Indian subcontinent 14 4.07 (2.39 to 6.95) 16 2.22 (1.56 to 3.16)
Latin America 17 1.13 (1.02 to 1.25) 27 1.32 (1.22 to 1.42)
North America 2 1.00 (0.75 to 1.34) 3 1.79 (1.35 to 2.37)
Northern and Eastern Europe 6 1.45 (1.26 to 1.67) 10 1.29 (1.14 to 1.45)
Oceania 4 1.44 (1.29 to 1.62) 8 1.21 (1.07 to 1.38)
Western Europe 13 1.27 (1.17 to 1.38) 17 1.30 (1.20 to 1.40)
Data are OR (95% CI) and are adjusted for gender, language and GNI category. Cuernavaca did not collect data on current maternal
smoking in both age groups.
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excess risk due to interaction, which indicates that the risk of
symptoms from the combined exposure is less than one would
have expected.
Population attributable risk (PAR) for the various exposures is
given in online table 3. The PAR for current maternal smoking
and the various asthma outcomes in both age groups range from
5.6% to 7.1%. Figure 3 shows the PAR for maternal and paternal
smoking. For example, if the prevalence of maternal smoking is
20% and paternal smoking is 25%, the PAR is 8%.
DISCUSSION
Main findings
This study has shown that parental smoking is associated with
an increased risk of diagnosis and symptoms of asthma, eczema
and rhinoconjunctivitis in childhood. The magnitude of the
association is greater for current smoking by mothers than
fathers, which may be due to children and adolescents spending
more time in the presence of their mothers than their fathers.
However, smoking by the mother and the father are both
important.
When we examined ‘severe asthma symptoms’, which is
clinically more meaningful, the magnitude of the ORs was even
greater than that seen with current wheeze. This result rein-
forces the role of ETS in the severity of asthma symptoms.
Furthermore, this suggests that ETS is related to asthma rather
than just trivial wheeze or other respiratory symptoms. The
magnitudes of the relative risks observed in this study are
modest, although consistent with other meta-analyses exam-
ining these relationships. However, given how prevalent
smoking is in some countries, ETS exposure is an important
contributor to the burden of asthma and allergies in those
countries. If maternal smoking is causally related to asthma then
it might account for 5e7% of asthma cases in the world.
Maternal smoking in the child’s ﬁrst year of life was associ-
ated with a greater risk of symptoms for all outcome categories
than current maternal smoking. Furthermore the magnitude of
the risk associated with exposure to both smoking in the ﬁrst
year of life and current smoking was not greater than those who
were only exposed to smoking in the ﬁrst year of life. This
indicates that early exposure to ETS is especially important.
However, it needs to be recognised that we did not collect
exposure data on smoking in pregnancy. As smoking in preg-
nancy and the ﬁrst year of the child’s life are highly correlated, it
is possible that maternal smoking in the child’s ﬁrst year of life is
a marker for smoking in pregnancy and that this is the more
important factor. This study is not able to elucidate this.
We showed clear evidence of a doseeresponse effect for
current maternal and paternal smoking on all the asthma
outcomes; that is, the more the mother or father smoked, the
greater the likelihood that the child or adolescent would develop
Table 3 Association between amount currently smoked by the parents and symptoms of asthma, eczema and rhinoconjunctivitis at 6e7 years of
age
Symptom
Current paternal smoking Current maternal smoking
1e9 cigarettes 10e19 cigarettes 20+ cigarettes 1e9 cigarettes 10e19 cigarettes 20+ cigarettes
Current wheeze 1.06 (1.00 to 1.12) 1.15 (1.08 to 1.22) 1.27 (1.19 to 1.35) 1.25 (1.17 to 1.34) 1.29 (1.20 to 1.38) 1.44 (1.31 to 1.59)
Severe asthma symptoms 1.05 (0.96 to 1.15) 1.22 (1.12 to 1.34) 1.42 (1.30 to 1.56) 1.27 (1.15 to 1.40) 1.35 (1.22 to 1.50) 1.56 (1.36 to 1.80)
Asthma ever 1.03 (0.97 to 1.10) 1.11 (1.04 to 1.18) 1.18 (1.11 to 1.26) 1.18 (1.09 to 1.27) 1.29 (1.20 to 1.40) 1.37 (1.24 to 1.52)
Current eczema symptoms 1.08 (1.02 to 1.15) 1.04 (0.97 to 1.11) 1.11 (1.04 to 1.20) 1.17 (1.08 to 1.26) 1.13 (1.04 to 1.23) 1.15 (1.02 to 1.30)
Current rhinoconjunctivitis symptoms 1.04 (0.98 to 1.11) 1.06 (0.99 to 1.13) 1.10 (1.03 to 1.18) 1.18 (1.09 to 1.27) 1.02 (0.94 to 1.11) 1.14 (1.02 to 1.28)
Eczema symptoms without wheeze 1.08 (1.01 to 1.16) 1.01 (0.94 to 1.09) 1.02 (0.94 to 1.11) 1.07 (0.98 to 1.17) 1.11 (1.00 to 1.22) 1.08 (0.94 to 1.25)
Rhinoconjunctivitis symptoms
without wheeze
1.04 (0.97 to 1.12) 0.98 (0.91 to 1.07) 1.00 (0.92 to 1.09) 1.07 (0.98 to 1.17) 0.92 (0.82 to 1.03) 1.05 (0.90 to 1.21)
Data are OR (95% CI) and are adjusted for gender, language, region and GNI category. Reference group is 0 cigarettes per day.
Table 4 Association between combinations of smoking by the parents and symptoms of asthma, eczema and rhinoconjunctivitis at 6e7 and
13e14 years of age
Symptom Mother only smokes Father only smokes Mother and father smoke RERI
6e7 years
Current wheeze 1.31 (1.22 to 1.41) 1.13 (1.08 to 1.18) 1.37 (1.29 to 1.45) 0.071 (0.182 to 0.040)
Severe asthma symptoms 1.31 (1.18 to 1.46) 1.19 (1.11 to 1.27) 1.46 (1.34 to 1.59) 0.042 (0.205 to 0.121)
Asthma ever 1.28 (1.19 to 1.38) 1.07 (1.02 to 1.12) 1.29 (1.22 to 1.38) 0.057 (0.168 to 0.054)
Current eczema symptoms 1.15 (1.06 to 1.24) 1.07 (1.02 to 1.12) 1.19 (1.11 to 1.27) 0.029 (0.136 to 0.078)
Current rhinoconjunctivitis symptoms 1.13 (1.04 to 1.23) 1.07 (1.02 to 1.12) 1.16 (1.09 to 1.24) 0.035 (0.141 to 0.070)
Eczema symptoms without wheeze 1.06 (0.97 to 1.16) 1.03 (0.98 to 1.09) 1.13 (1.05 to 1.22) 0.040 (0.075 to 0.155)
Rhinoconjunctivitis symptoms without wheeze 1.08 (0.98 to 1.19) 1.04 (0.98 to 1.09) 1.06 (0.98 to 1.15) 0.052 (0.173 to 0.069)
13e14 years
Current wheeze 1.27 (1.19 to 1.36) 1.13 (1.07 to 1.18) 1.43 (1.36 to 1.51) 0.040 (0.066 to 0.146)
Current wheeze (video) 1.38 (1.25 to 1.52) 1.17 (1.10 to 1.25) 1.50 (1.39 to 1.63) 0.046 (0.203 to 0.111)
Severe asthma symptoms 1.28 (1.18 to 1.39) 1.16 (1.09 to 1.23) 1.57 (1.47 to 1.67) 0.128 (0.004 to 0.260)
Asthma ever 1.16 (1.09 to 1.23) 1.04 (0.99 to 1.08) 1.21 (1.16 to 1.28) 0.021 (0.064 to 0.107)
Current eczema symptoms 1.20 (1.10 to 1.30) 1.17 (1.10 to 1.23) 1.33 (1.24 to 1.42) 0.040 (0.160 to 0.080)
Current rhinoconjunctivitis symptoms 1.15 (1.08 to 1.23) 1.12 (1.07 to 1.17) 1.27 (1.21 to 1.34) 0.000 (0.092 to 0.093)
Eczema symptoms without wheeze 1.16 (1.06 to 1.27) 1.16 (1.10 to 1.23) 1.18 (1.10 to 1.27) 0.139 (0.266 to 0.012)
Rhinoconjunctivitis symptoms without wheeze 1.06 (0.99 to 1.13) 1.10 (1.05 to 1.15) 1.18 (1.11 to 1.25) 0.022 (0.068 to 0.113)
Data are OR (95% CI) and are adjusted for gender, language, region and GNI category. Reference group is neither parent smokes.
RERI, relative excess risk due to interaction between the two smoking exposures.
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asthma symptoms. The presence of a doseeresponse effect is
strong evidence for a causal relationship.
We found a weak but consistent association between ETS and
symptoms of eczema. A doseeresponse effect relationship was
not seen between amount smoked and symptoms of eczema. In
contrast to asthma, there have been fewer studies of the asso-
ciation between smoking and eczema. Smoking has been shown
to increase the risk in adults in Sweden,12 but not in Norway.13
In children aged 3 years, in utero and postnatal exposure were
not associated with eczema14 nor was an effect seen in children
aged 0e12 years.15 However, in a study of children aged 6 years
an increased risk of eczema was associated with urinary cotinine
levels.16
Finally we found that the association between ETS and
symptoms of rhinoconjuctivitis was even weaker and for many
of the analyses did not reach statistical signiﬁcance. Further-
more, a doseeresponse relationship was not seen between the
amount smoked and symptoms of rhinoconjunctivitis. Studies
examining the association between smoking and rhino-
conjunctivitis are also conﬂicting. One study reported a reduced
risk of rhinoconjunctivitis for adult smokers and their children.17
Another showed a decreased risk of hayfever in adolescents who
were exposed to tobacco in utero.18 However, in the ISAAC
Phase Two Study there was an increased risk of rhino-
conjunctivitis in children aged 9e11 years who had been
exposed to maternal smoking during pregnancy.19
Strengths and limitations
The strengths of this multicentre study were its power, size and
multinational nature. The younger age group comprised 75
centres from 32 countries with 220 407 children and the
adolescent group comprised 118 centres from 53 countries with
350 654 adolescents. As a result, we established the consistency
of the association of ETS with the presence of asthma and other
allergic disorders in various populations with different preva-
lences of asthma and allergies, different exposure levels and
different cultures and economic development. Many previous
studies have been conducted in developed countries and
the meta-analyses reﬂect this.2 This study extends the meta-
analyses by including many countries that are less developed and
markedly increased the size and number of the studies exam-
ining these relationships. We mainly used self-reported symp-
toms rather than doctors’ diagnoses to avoid major diagnostic
differences related to access to medical care, language and
medical practice. Publication bias has been avoided in this study
as the data from each centre in the study were included.
Limitations of this study also need to be considered. The
outcomes and exposures were assessed by questionnaire, which
were completed by the parents for the younger age group and by
the participants in the adolescent age group. Although it is likely
that the parent who completed the questionnaire would be
more accurate about their own tobacco use than that smoked by
the other parent, we did not record which parent completed the
questionnaire. This might lead to misclassiﬁcation, which would
reduce the chance of identifying associations, but is unlikely to
result in any systematic bias. Selection bias is also unlikely as the
response rate from centres included in these analyses was high.
The major limitation was absence of data on smoking by the
participants themselves. Smoking by 6e7 year olds is unlikely,
but is more likely in the adolescents. Adolescents who smoke are
at greater risk of wheezing than those who had never smoked.20
However, there was consistency of ﬁndings across the two age
groups, which suggests this potential bias is not important.
Implications
The association of ETS with asthma fulﬁls the criteria for
a causal relationship.21 The association is moderately strong; the
results were generally consistent across each of the centres; and
a doseeresponse relationship was seen for asthma, but not
eczema and rhinoconjunctivitis.
Conclusion
In summary, this study has conﬁrmed the importance of
maternal smoking, especially early in the child’s life, and the
separate and additional effect of paternal smoking. The presence
of a doseeresponse effect relationship with symptoms of
asthma suggests that the relationship may be causal. However,
for eczema and rhinoconjunctivitis causality is less certain.
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Table 5 Association between combinations of maternal smoking in the child’s first year of life and current smoking and symptoms of asthma,
eczema and rhinoconjunctivitis at 67 years of age
Symptom First year of life only Current only Both times RERI
Current wheeze 1.38 (1.24 to 1.53) 1.23 (1.14 to 1.32) 1.39 (1.31 to 1.47) 0.218 (0.432 to 0.004)
Severe asthma symptoms 1.36 (1.17 to 1.58) 1.21 (1.09 to 1.34) 1.48 (1.36 to 1.61) 0.093 (0.405 to 0.219)
Asthma ever 1.41 (1.27 to 1.56) 1.20 (1.11 to 1.30) 1.37 (1.28 to 1.45) 0.247 (0.462 to 0.031)
Current eczema symptoms 1.19 (1.06 to 1.33) 1.11 (1.03 to 1.20) 1.21 (1.13 to 1.29) 0.089 (0.293 to 0.114)
Current rhinoconjunctivitis symptoms 1.18 (1.05 to 1.33) 1.07 (0.99 to 1.16) 1.16 (1.09 to 1.24) 0.097 (0.299 to 0.106)
Eczema symptoms without wheeze 1.13 (0.99 to 1.29) 1.10 (1.01 to 1.20) 1.11 (1.02 to 1.20) 0.086 (0.317 to 0.145)
Rhinoconjunctivitis symptoms without wheeze 1.08 (0.93 to 1.25) 1.03 (0.94 to 1.13) 1.03 (0.94 to 1.12) 0.123 (0.343 to 0.096)
Data are OR (95% CI) and are adjusted for gender, language, region and GNI category. Reference group: mother non-smoker for first year of child’s life and non-smoker now.
RERI, relative excess risk due to interaction between the two smoking exposures.
Figure 3 The population attributable risk for current wheeze for the
combinations of the prevalence of maternal and paternal smoking
assuming they are independent.
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